Indeed, blockade of both PD-1 and CTLA-4 showed improved clinical efficacy in patients with, amongst others, melanoma (13) and advanced non-small-cell lung cancer (14) and hepatocellular carcinoma (15). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.